Arcutis Biotherapeutics Financial Statements
NASDAQ: ARQTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arcutis Biotherapeutics revenue and earnings
In fiscal 2025, Arcutis Biotherapeutics generated $376.1 million in revenue, up 91.3% from fiscal 2024, its 4th consecutive year of revenue growth. Arcutis Biotherapeutics reported a net loss of $16.1 million, compared with a loss of $140.0 million a year earlier. Gross margin was 90.2% (flat year over year) and operating margin -3.3%.
Diluted earnings per share came in at -$0.13.
Summary generated from market data by MetaCap's automated system. Methodology
Arcutis Biotherapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 376.07M | 196.54M | 59.61M | 3.69M | 0 | 0 | — | — |
| Revenue growth (YoY) | +91.34% | +229.74% | +1517.09% | — | — | — | — | — |
| Cost of Revenue | 36.70M | 19.13M | 4.99M | 754.00K | 0 | — | — | — |
| Gross Profit | 339.38M | 177.41M | 54.62M | 2.93M | 0 | — | — | — |
| Operating Expenses | 351.60M | 305.81M | 295.72M | 305.31M | 206.53M | 136.65M | 43.13M | 19.73M |
| Research & Development | 77.05M | 76.42M | 110.58M | 182.44M | 145.56M | 115.31M | 36.52M | 17.94M |
| Selling, General & Admin | 274.55M | 229.39M | 185.15M | 122.12M | 60.97M | — | — | — |
| Operating Income | -12.23M | -128.40M | -241.10M | -301.63M | -206.53M | -136.65M | -43.13M | -19.73M |
| Interest Expense | 12.08M | 27.17M | 29.71M | 15.65M | 0 | 0 | — | — |
| Other Income (Expense) | 443.00K | 47.00K | -731.00K | -9.83M | 173.00K | 967.00K | 1.14M | 480.00K |
| Pretax Income | -8.24M | -130.37M | -255.65M | -311.46M | -206.36M | — | — | — |
| Income Tax | 1.17M | 647.00K | 3.11M | 0 | 0 | 0 | 0 | 0 |
| Net Income | -16.14M | -140.04M | -262.14M | -311.46M | -206.36M | -135.68M | -42.00M | -19.25M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.13 | -1.16 | -3.78 | -5.66 | -4.18 | -3.80 | -22.78 | -15.53 |
| EPS (Diluted) | -0.13 | -1.16 | -3.78 | -5.66 | -4.18 | -3.80 | -22.78 | -15.53 |
| Shares Outstanding (Basic) | 127.23M | 120.96M | 69.31M | 55.03M | 49.41M | 35.67M | 1.84M | 1.24M |
| Shares Outstanding (Diluted) | 127.23M | 120.96M | 69.31M | 55.03M | 49.41M | 35.67M | 1.84M | 1.24M |
| EBITDA | -11.53M | -127.80M | -240.30M | -301.00M | -206.07M | -136.52M | -43.06M | -19.73M |
| Gross Margin | 90.24% | 90.27% | 91.63% | 79.54% | — | — | — | — |
| Operating Margin | -3.25% | -65.33% | -404.49% | -8183.04% | — | — | — | — |
| Net Margin | -4.29% | -71.25% | -439.79% | -8449.76% | — | — | — | — |
This table shows 8 annual periods of Arcutis Biotherapeutics's income statement, from FY 2025 back to FY 2018, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow ARQT's reporting calendar. What is a income statement?